Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
EBIX Ebix Inc
FCRD First Eagle Alternative Capital BDC Inc
RWAY Runway Growth Finance Corp
LITB LightInTheBox Holding Co Ltd
UEC Uranium Energy Corp
NEE Nextera Energy Inc
MANT ManTech International Corp
AMPE Ampio Pharmaceuticals Inc
MA Mastercard Inc
Go

Health Care : Biotechnology | Small Cap Value

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price: $4.55

Day's Change: 0.23 (5.32%)

Bid: --

Ask: --

B/A Size: --

Day's High: 4.64

Day's Low: 4.22

Volume (Light) Volume: 171,188 10-day average volume: 351,972: 171,188

January 05, 2022
7:01 am ET	Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022 Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences...(PR Newswire)
December 14, 2021
8:30 am ET	Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences? InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)
December 06, 2021
8:30 am ET	Thinking about buying stock in Adicet Bio, GCP Applied Technologies, Aeglea Bio Therapeutics, Fulcrum Therapeutics, or Ardelyx? InvestorsObserver issues critical PriceWatch Alerts for ACET, GCP, AGLE, FULC, and ARDX. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)
6:30 am ET	Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE...(PR Newswire)
December 05, 2021
6:00 pm ET	Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor...(PR Newswire)
November 16, 2021
7:01 am ET	Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to...(PR Newswire)
November 04, 2021
7:01 am ET	Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter...(PR Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and